Topic: Clostridium difficile


4. Pfizer

Pfizer’s vaccines business has for years centered on Prevnar 13, the world’s bestselling vaccine, and 2017 was no exception. But the company wants to change that—and for good reason.
Sanofi Pasteur HQ

3. Sanofi

By the numbers, Sanofi’s vaccines business did quite well in 2017. Revenue grew an impressive 8.3% to reach €5.1 billion ($6.12 billion). But beyond the income statement, last year wasn’t without headline-hogging controversies and setbacks.